ISSY-LES-MOULINEAUX, France, March 23, 2006 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson Consumer France SAS said it has entered into an agreement to acquire Groupe Vendome, a privately held French marketer of adult and baby skin care products.
This acquisition is subject to certain closing conditions and regulatory approvals, and is expected to be completed within the second quarter of 2006. The terms were not disclosed.
Groupe Vendome's brands include Le Petit Marseillais, a line of shower gels, soaps, baths and hair care products; Laboratories Vendome, a dermatological solutions brand with body cleansers and moisturizers; and Prim'Age, a baby toiletries brand. The company maintains its headquarters in the Dijon region of France.
"The acquisition of Groupe Vendome will allow us to enhance our adult and baby skin care businesses," said Claudio Cavicchioli, President of Johnson & Johnson Consumer France. "We are looking forward to building on the outstanding equity that the Groupe Vendome brands enjoy in the consumer marketplace. In particular, Le Petit Marseillais is a trusted family brand with more than 100 years of heritage behind it."
Johnson & Johnson Consumer France SAS is a subsidiary of Johnson & Johnson. Based in Issy-Les-Moulineaux, France, Johnson & Johnson Consumer France markets such well-known skin care brands as RoC(R) and NEUTROGENA(R) as well as the COMPEED(R) wound care brand.
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include: satisfaction of closing conditions and receipt of regulatory approvals for the acquisition; general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended January 1, 2006. Copies of this Form 10-K are available online at www.sec.gov or on request from the Company. The Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments.)
For more information on Johnson & Johnson, please visit the Company's website at http://www.jnj.com.
SOURCE Johnson & Johnson Consumer France SAS
Press, Iris Grossman, +1-908-874-1838, or Investor, Louise Mehrotra, +1-732-524-6491, or Stan Panasewicz, +1-732-524-2524, all of Johnson & Johnson
Copyright (C) 2006 PR Newswire. All rights reserved.
News Provided by COMTEX